Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Stryker Corporation — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 73.3× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Stryker Corporation pays a 1.27% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and Stryker Corporation for 21 Days on average.
| QQQE | SYK | |
|---|---|---|
Market Cap | $1.45B | $106.24B |
Volume | 323,568 | 2,982,001 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $388.35 |
52-Week Low | $96.06 | $269.75 |
Typical Hold Time | 48 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.03, down 0.71% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Recent news highlights its equal-weight strategy reducing technology concentration compared to market-cap weighted peers. The fund provides diversified exposure to large-cap growth stocks within the Nasdaq-100 index.
The outlook for QQQE is supported by its tactical appeal as an equal-weight alternative, though it carries risks tied to Nasdaq performance and sector concentration. Investor sentiment appears cautiously optimistic given recent favorable coverage comparing it to QQQ. The absence of traditional valuation ratios is typical for an ETF tracking an index.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
